E. Lee

发表

Characterization of initial key steps of IL-17 receptor B oncogenic signaling for targeted therapy of pancreatic cancer

Y. Jeng, L. Tsai, Wen-Hwa Lee, 2021, Science Translational Medicine.

Antitumor agents. 272. Structure-activity relationships and in vivo selective anti-breast cancer activity of novel neo-tanshinlactone analogues.

A. Brossi, M. Hung, J. Hsu, 2010, Journal of medicinal chemistry.

Progesterone Receptor A Stability Is Mediated by Glycogen Synthase Kinase-3β in the Brca1-deficient Mammary Gland*

Y. Li, Shaohui Wang, P. Hsu, 2013, The Journal of Biological Chemistry.

GSK-3β and PR-A stabilization in BRCA1-deficient cells

Y. Li, Shaohui Wang, P. Hsu, 2013 .

Validation of Transgenic Mammary Cancer Models: Goals of the NCI Mouse Models of Human Cancer Consortium and the Mammary Cancer CD-ROM

R. Cardiff, E. Liu, L. Wakefield, 2002, Transgenic Research.

Antitumor agents 279. Structure-activity relationship and in vivo studies of novel 2-(furan-2-yl)naphthalen-1-ol (FNO) analogs as potent and selective anti-breast cancer agents.

Yizhou Dong, K. Lee, S. Morris-Natschke, 2011, Bioorganic & medicinal chemistry letters.

Tumor Microemboli as a Prognostic Marker in Patients with Pancreatic Ductal Adenocarcinoma.

Y. Jeng, Wen-Hwa Lee, Yu-Ting Chang, 2016 .

Detection of kinase and phosphatase activities.

S. Post, E. Lee, 2004, Methods in molecular biology.

Antitumor Agents. 282. 2'-(R)-O-acetylglaucarubinone, a quassinoid from Odyendyea gabonensis as a potential anti-breast and anti-ovarian cancer agent.

M. Hung, D. Newman, G. Cragg, 2010, Journal of natural products.

Tissue-specific tumor suppression by BRCA1

E. Lee, Serena Abbondante, 2014, Proceedings of the National Academy of Sciences.

Antitumor agents. 289. Design, synthesis, and anti-breast cancer activity in vivo of 4-amino-2H-benzo[h]chromen-2-one and 4-amino-7,8,9,10-tetrahydro-2H-benzo[h]chromen-2-one analogues with improved water solubility.

Yizhou Dong, K. Lee, S. Morris-Natschke, 2012, Journal of natural products.

Developmental phenotype of a membrane only estrogen receptor alpha (MOER) mouse.

E. Levin, M. Razandi, A. Pedram, 2009 .

Oncogenes and tumor suppressor genes.

W. Muller, William J Muller, E. Lee, 2010, Cold Spring Harbor perspectives in biology.

Pten haploinsufficiency accelerates formation of high-grade astrocytomas.

R. Mason, D. Burns, Hong Wu, 2008, Cancer research.

Expression of mutant p53 proteins implicates a lineage relationship between neural stem cells and malignant astrocytic glioma in a murine model.

Y. Wang, Peng Zhang, P. Mckeever, 2009, Cancer cell.

Estrogen inhibits ATR signaling to cell cycle checkpoints and DNA repair.

E. Levin, M. Razandi, A. Pedram, 2009, Molecular biology of the cell.

Cellular 5-hydroxylmethylcytosine content determines tumorigenic potential and prognosis of pancreatic ductal adenocarcinoma.

Y. Jeng, Wen-Hwa Lee, Yu-Ting Chang, 2018, American journal of cancer research.

Coupled Transcriptional and Translational Control of Cyclin-Dependent Kinase Inhibitor p18INK4cExpression during Myogenesis

D. Franklin, Y. Xiong, K. Hsiao, 1998, Molecular and Cellular Biology.

High Glucose Triggers Nucleotide Imbalance through O-GlcNAcylation of Key Enzymes and Induces KRAS Mutation in Pancreatic Cells.

Y. Jeng, Wen-Hwa Lee, Yu-Ting Chang, 2019, Cell metabolism.

Somatic Mutation of p53 Leads to Estrogen Receptor α-Positive and -Negative Mouse Mammary Tumors with High Frequency of Metastasis

S. Hilsenbeck, R. Cardiff, K. Kang, 2004, Cancer Research.

Inactivation of CtIP Leads to Early Embryonic Lethality Mediated by G1 Restraint and to Tumorigenesis by Haploid Insufficiency

F. Liu, Yumay Chen, Phang-lang Chen, 2005, Molecular and Cellular Biology.

Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors.

G. Mills, G. Hortobagyi, E. Stanbridge, 2008, Cancer research.

Mediated Mouse Mammary Tumors − Brca 1 / p 53 Cancer Stem Cells Contribute to Cisplatin Resistance in Updated

G. Mills, G. Hortobagyi, E. Stanbridge, 2008 .

Prevention of Brca1-Mediated Mammary Tumorigenesis in Mice by a Progesterone Antagonist

Y. Li, Wen-Hwa Lee, Suh-Chin J. Lin, 2006, Science.

RANKL/RANK control Brca1 mutation-driven mammary tumors

H. Heyn, M. Pujana, C. Lázaro, 2016, Cell Research.

ErbB2 overexpression in p53‐inactivated mammary epithelial cells

E. Lee, Jin Won Yang, Keon Wook Kang, 2006, FEBS letters.

Identification of an integrated SV40 T/t-antigen cancer signature in aggressive human breast, prostate, and lung carcinomas with poor prognosis.

Aleksandra M. Michalowska, C. Deng, J. Shih, 2007, Cancer research.

Removal of BRCA1/CtIP/ZBRK1 repressor complex on ANG1 promoter leads to accelerated mammary tumor growth contributed by prominent vasculature.

Wen-Hwa Lee, Yung-Ming Jeng, Y. Jeng, 2006, Cancer cell.

Clinical Significance of Circulating Tumor Microemboli as a Prognostic Marker in Patients with Pancreatic Ductal Adenocarcinoma.

Y. Jeng, Wen-Hwa Lee, Yu-Ting Chang, 2016, Clinical chemistry.

Targeting IL-17B–IL-17RB signaling with an anti–IL-17RB antibody blocks pancreatic cancer metastasis by silencing multiple chemokines

Y. Jeng, Che Ma, Y. Tien, 2015, The Journal of experimental medicine.

Promotion of BRCA1-associated triple-negative breast cancer by ovarian hormones

E. Lee, 2008, Current opinion in obstetrics & gynecology.

Developmental Phenotype of a Membrane Only Estrogen Receptor α (MOER) Mouse*

E. Levin, M. Razandi, A. Pedram, 2009, Journal of Biological Chemistry.

Brca1/p53 deficient mouse breast tumor hemodynamics during hyperoxic respiratory challenge monitored by a novel wide-field functional imaging (WiFI) system

Bruce J. Tromberg, Bernard Choi, Albert E. Cerussi, 2009, BiOS.

Novel small molecules disrupting Hec1/Nek2 interaction ablate tumor progression by triggering Nek2 degradation through a death-trap mechanism

Wen-Hwa Lee, G. Wu, W. Chen, 2014, Oncogene.